/home/corante/public_html/pipeline/ en-us derekb.lowe@gmail.com 2013-05-23T06:41:12-05:00 hourly 1 2000-01-01T12:00+00:00 http://pipeline.corante.com/archives/2013/05/23/another_look_at_marketing_vs_rd_in_pharma.php FiercePharma has some good figures to back up my posts the other day on R&D spending versus marketing. I mentioned how many people, when they argue that drug companies spend more on marketing than they do on research, are taking... 76434@/home/corante/public_html/pipeline/ Business and Markets 2013-05-23T06:41:12-05:00 http://pipeline.corante.com/archives/2013/05/16/the_atlantic_on_drug_rd.php "Can you respond to this tripe?" asked one of the emails that sent along this article in The Atlantic. I responded that I was planning to, but that things were made more complicated by my being extensively quoted in said... 76420@/home/corante/public_html/pipeline/ Drug Development 2013-05-16T06:55:00-05:00 http://pipeline.corante.com/archives/2013/05/09/mercks_liptruzet_a_cause_for_shame.php Vytorin's been discussed several times around here. The combination of Zetia (ezetimibe), the cholesterol absorption inhibitor discovered at Schering-Plough, with Merck's simvastatin looked as if it should be a very effective cholesterol-lowering medication, but the real-world data have been consistentlypuzzling.... 76402@/home/corante/public_html/pipeline/ Cardiovascular Disease 2013-05-09T08:12:07-05:00 http://pipeline.corante.com/archives/2013/04/29/costing_just_too_much.php There's been a lot of rumbling recently about the price of new cancer drugs (see this article for a very typical reaction). It's a topic that's come up around here many times, as would be only natural - scrolling back... 76376@/home/corante/public_html/pipeline/ Drug Prices 2013-04-29T12:44:48-05:00 http://pipeline.corante.com/archives/2013/02/11/phrma_and_why_people_dislike_the_drug_industry.php John LaMattina takes off after PhRMA's effectiveness here at Forbes. His two points are release of clinical trial data and openness about consultant payments to physicians. And I agree with him on both of those - as I've said here... 76204@/home/corante/public_html/pipeline/ Regulatory Affairs 2013-02-11T09:19:40-05:00 http://pipeline.corante.com/archives/2012/12/20/a_new_book_on_the_drug_industry_and_its_image.php John LaMattina (ex-head of Pfizer's global R&D) has a new book out about the industry, called Devalued and Distrusted. He tells Pharmalot that he got the idea to write a sequel to his earlier book, Drug Truths, when he appeared... 76087@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2012-12-20T07:08:46-05:00 http://pipeline.corante.com/archives/2012/12/14/lamattina_on_angell.php John LaMattina takes on Marcia Angell and her recent interview. It sounds like he made it farther into the podcast than I could: “The drug companies do almost no innovation nowadays….. All they have to do is the late development.... 76072@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2012-12-14T08:35:22-05:00 http://pipeline.corante.com/archives/2012/12/05/offlabel_promotion_is_legal_you_say.php You'll have seen the headlines about off-label promotion of drugs by pharma companies. No, not the ones that decry it as a shady marketing technique, punishable by huge fines. I mean the ones about how a federal court has ruled... 76046@/home/corante/public_html/pipeline/ Business and Markets 2012-12-05T07:12:44-05:00 http://pipeline.corante.com/archives/2012/12/03/marcia_angells_interview_i_just_cant.php I have tried to listen to this podcast with Marcia Angell, on drug companies and their research, but I cannot seem to make it all the way through. I start shouting at the screen, at the speakers, at the air... 76041@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2012-12-03T11:22:57-05:00 http://pipeline.corante.com/archives/2012/10/11/gsk_opens_up_its_trial_data.php GlaxoSmithKline took an unusual step today: they announced that they're opening up clinical trial data: "GSK is fully committed to sharing information about its clinical trials. It posts summary information about each trial it begins and shares the summary results... 75926@/home/corante/public_html/pipeline/ Clinical Trials 2012-10-11T10:36:01-05:00 http://pipeline.corante.com/archives/2012/08/09/getting_drug_research_really_really_wrong.php The British Medical Journal says that the "widely touted innovation crisis in pharmaceuticals is a myth". The British Medical Journal is wrong. There, that's about as direct as I can make it. But allow me to go into more detail,... 75801@/home/corante/public_html/pipeline/ Business and Markets 2012-08-09T10:45:39-05:00 http://pipeline.corante.com/archives/2012/06/22/mercks_madagascar_marketing_mess.php OK, it's time to haul the marketing guys back in again. Via Pharmalot, I see that Merck, in its capacity now as Merck Schering-Plough, is promoting Claritin via a tie-in with the kid's movie "Madagascar 3". That is certainly the... 75717@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2012-06-22T07:03:11-05:00 http://pipeline.corante.com/archives/2011/06/28/dtc_advertising_is_that_where_things_fell_apart.php Over at Forbes, Matthew Herper has a provocative comment from a former Merck executive, Peter DeVillbiss. He's wondering when and how drug companies lost the public standing that they used to have (remember, Merck used to be the "most admired... 75067@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2011-06-28T07:01:51-05:00 http://pipeline.corante.com/archives/2011/06/22/the_nih_and_conflicts_of_interest.php The NIH has, it appears, been getting quite sensitive about conflicts of interest. There have been some rather ugly scenes involving ghostwritten articles (and entire books), and NIH director Francis Collins has said that the agency's guidelines are in the... 75059@/home/corante/public_html/pipeline/ Academia (vs. Industry) 2011-06-22T08:54:58-05:00 http://pipeline.corante.com/archives/2011/06/07/even_worse_than_reality.php I found this article in The American Scholar via Arts and Letters Daily, entitled "Flacking for Big Pharma". As you might have possibly guessed from the title, it's a broadside against the advertising practices of the drug industry, and particularly... 75031@/home/corante/public_html/pipeline/ Why Everyone Loves Us 2011-06-07T10:19:20-05:00